Free Trial

Alnylam Pharmaceuticals (ALNY) Financials

Alnylam Pharmaceuticals logo
$240.01 +2.24 (+0.94%)
As of 04/14/2025 04:00 PM Eastern
Annual Income Statements for Alnylam Pharmaceuticals

Annual Income Statements for Alnylam Pharmaceuticals

This table shows Alnylam Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders
-290 -410 -491 -761 -886 -858 -853 -1,131 -440 -278
Consolidated Net Income / (Loss)
-290 -410 -491 -761 -886 -858 -853 -1,131 -440 -278
Net Income / (Loss) Continuing Operations
-290 -410 -491 -761 -886 -858 -853 -1,131 -440 -278
Total Pre-Tax Income
-290 -410 -491 -761 -885 -856 -852 -1,127 -434 -377
Total Operating Income
-296 -425 -500 -815 -939 -828 -709 -785 -282 -177
Total Gross Profit
41 47 90 73 195 415 704 869 1,518 1,925
Total Revenue
41 47 90 75 220 493 844 1,037 1,828 2,248
Operating Revenue
41 47 90 75 220 493 844 1,037 1,828 2,248
Total Cost of Revenue
0.00 0.00 0.00 1.80 25 78 140 169 310 323
Operating Cost of Revenue
- - 0.00 1.80 25 78 140 169 310 323
Total Operating Expenses
337 472 590 888 1,134 1,243 1,413 1,654 1,800 2,102
Selling, General & Admin Expense
61 89 199 382 479 588 621 771 796 976
Research & Development Expense
276 382 391 505 655 655 792 883 1,004 1,126
Total Other Income / (Expense), net
5.94 14 9.21 54 54 -27 -143 -342 -151 -200
Interest Expense
- - - 0.00 0.00 84 143 233 121 142
Interest & Investment Income
5.86 8.31 12 29 33 - 1.58 25 96 122
Other Income / (Expense), net
0.08 6.17 -3.02 25 21 57 -2.05 -134 -126 -181
Income Tax Expense
- 0.00 0.00 0.82 0.86 2.68 0.68 4.16 6.73 -99
Basic Earnings per Share
($3.45) ($4.79) ($5.42) ($7.57) ($8.11) ($7.46) ($7.20) ($9.30) ($3.52) ($2.18)
Weighted Average Basic Shares Outstanding
83.99M 85.60M 90.55M 100.59M 109.26M 114.99M 118.45M 121.69M 124.91M 127.65M
Diluted Earnings per Share
($3.45) ($4.79) ($5.42) ($7.57) ($8.11) ($7.46) ($7.20) ($9.30) ($3.52) ($2.18)
Weighted Average Diluted Shares Outstanding
83.99M 85.60M 90.55M 100.59M 109.26M 114.99M 118.45M 121.69M 124.91M 127.65M
Weighted Average Basic & Diluted Shares Outstanding
83.99M 85.60M 90.55M 100.59M 109.26M 114.99M 120.21M 124.13M 125.95M 129.46M

Quarterly Income Statements for Alnylam Pharmaceuticals

This table shows Alnylam Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders
-406 -207 -174 -276 148 -138 -66 -17 -112 -84
Consolidated Net Income / (Loss)
-406 -207 -174 -276 148 -138 -66 -17 -112 -84
Net Income / (Loss) Continuing Operations
-406 -207 -174 -276 148 -138 -66 -17 -112 -84
Total Pre-Tax Income
-406 -207 -172 -274 151 -138 -64 -11 -109 -194
Total Operating Income
-258 -189 -150 -230 214 -116 -43 49 -77 -105
Total Gross Profit
223 284 264 233 666 354 428 591 415 490
Total Revenue
264 335 319 319 751 440 494 660 501 593
Operating Revenue
264 335 319 319 751 440 494 660 501 593
Total Cost of Revenue
41 51 55 85 84 86 66 69 86 103
Operating Cost of Revenue
41 51 55 85 84 86 66 69 86 103
Total Operating Expenses
481 472 414 463 452 470 472 543 492 596
Selling, General & Admin Expense
236 210 184 215 199 198 211 248 221 295
Research & Development Expense
245 262 231 249 253 272 261 294 271 300
Total Other Income / (Expense), net
-148 -18 -23 -44 -63 -21 -20 -60 -32 -89
Interest Expense
118 30 29 30 31 31 35 33 34 39
Interest & Investment Income
7.82 14 19 21 25 30 30 29 32 31
Other Income / (Expense), net
-38 -2.57 -12 -35 -58 -20 -15 -56 -30 -81
Income Tax Expense
-0.02 0.47 1.74 1.82 2.99 0.18 2.35 5.72 2.91 -110
Basic Earnings per Share
($3.32) ($1.69) ($1.40) ($2.21) $1.18 ($1.09) ($0.52) ($0.13) ($0.87) ($0.66)
Weighted Average Basic Shares Outstanding
122.17M 121.69M 124.11M 124.66M 125.22M 124.91M 126.14M 126.73M 128.59M 127.65M
Diluted Earnings per Share
($3.32) ($1.69) ($1.40) ($2.21) $1.15 ($1.06) ($0.52) ($0.13) ($0.87) ($0.66)
Weighted Average Diluted Shares Outstanding
122.17M 121.69M 124.11M 124.66M 131.34M 124.91M 126.14M 126.73M 128.59M 127.65M
Weighted Average Basic & Diluted Shares Outstanding
123.03M 124.13M 124.53M 125.00M 125.49M 125.95M 126.49M 128.38M 128.98M 129.46M

Annual Cash Flow Statements for Alnylam Pharmaceuticals

This table details how cash moves in and out of Alnylam Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Change in Cash & Equivalents
106 13 452 -224 127 -51 323 46 -54 154
Net Cash From Operating Activities
-189 -308 -383 -563 -278 -615 -642 -541 104 -8.31
Net Cash From Continuing Operating Activities
-189 -308 -383 -563 -278 -615 -642 -541 104 -8.31
Net Income / (Loss) Continuing Operations
-290 -410 -491 -761 -886 -858 -853 -1,131 -440 -278
Consolidated Net Income / (Loss)
-290 -410 -491 -761 -886 -858 -853 -1,131 -440 -278
Depreciation Expense
19 15 12 15 17 35 48 44 54 57
Non-Cash Adjustments To Reconcile Net Income
47 72 95 170 164 170 227 445 345 402
Changes in Operating Assets and Liabilities, net
35 15 1.48 14 390 -1.44 -105 101 145 -189
Net Cash From Investing Activities
-321 143 -290 273 -418 -436 -273 169 -336 -117
Net Cash From Continuing Investing Activities
-321 143 -290 273 -418 -436 -273 169 -336 -117
Purchase of Property, Plant & Equipment
-13 -65 -104 -127 -140 -70 -76 -72 -62 -34
Purchase of Investments
-1,035 -909 -903 -1,119 -2,076 -2,052 -1,698 -2,075 -1,882 -1,712
Sale and/or Maturity of Investments
727 1,116 717 1,519 1,805 1,692 1,506 2,322 1,612 1,630
Other Investing Activities, net
- - 0.00 0.00 -7.00 -5.30 -4.20 -4.69 -4.44 -0.12
Net Cash From Financing Activities
616 178 1,125 65 823 995 1,247 426 172 294
Net Cash From Continuing Financing Activities
616 178 1,125 65 823 995 1,247 426 172 294
Repayment of Debt
- - -120 0.00 - 0.00 500 -762 0.00 0.00
Issuance of Debt
- 150 - 0.00 0.00 200 0.00 1,016 0.00 0.00
Issuance of Common Equity
617 28 1,245 65 853 300 246 259 147 303
Other Financing Activities, net
0.38 -0.60 - 0.00 -30 495 501 -88 25 -8.79
Effect of Exchange Rate Changes
- - - - -0.08 4.92 -9.02 -7.43 6.39 -15
Cash Interest Paid
- 1.10 2.43 - 0.17 0.00 25 45 32 68
Cash Income Taxes Paid
0.07 0.11 0.11 - - - - 2.65 6.02 14

Quarterly Cash Flow Statements for Alnylam Pharmaceuticals

This table details how cash moves in and out of Alnylam Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents
498 -207 -194 -14 375 -220 -130 286 131 -134
Net Cash From Operating Activities
-115 -132 -166 -59 359 -30 -82 124 44 -95
Net Cash From Continuing Operating Activities
-115 -132 -166 -59 359 -30 -82 124 44 -95
Net Income / (Loss) Continuing Operations
-406 -207 -174 -276 148 -138 -66 -17 -112 -84
Consolidated Net Income / (Loss)
-406 -207 -174 -276 148 -138 -66 -17 -112 -84
Depreciation Expense
11 14 14 13 13 13 14 15 14 14
Non-Cash Adjustments To Reconcile Net Income
237 61 67 101 108 69 77 120 78 127
Changes in Operating Assets and Liabilities, net
33 31 -86 93 80 58 -118 -3.84 50 -117
Net Cash From Investing Activities
314 -140 -76 -8.71 -11 -241 -68 34 -30 -53
Net Cash From Continuing Investing Activities
314 -140 -76 -8.71 -11 -241 -68 34 -30 -53
Purchase of Property, Plant & Equipment
-17 -22 -14 -16 -17 -15 -13 -8.02 -4.19 -9.09
Purchase of Investments
-223 -723 -485 -386 -421 -589 -460 -316 -450 -487
Sale and/or Maturity of Investments
558 605 423 394 432 364 405 358 424 443
Other Investing Activities, net
-5.00 0.38 - - - - - - - -0.12
Net Cash From Financing Activities
297 63 46 53 33 39 29 131 103 31
Net Cash From Continuing Financing Activities
297 63 46 53 33 39 29 131 103 31
Issuance of Common Equity
153 57 42 49 25 31 26 133 108 36
Other Financing Activities, net
-111 7.50 4.00 4.00 8.33 8.33 3.05 -1.28 -5.28 -5.28
Effect of Exchange Rate Changes
2.02 1.62 2.18 -0.13 -6.55 11 -9.94 -3.12 15 -17
Cash Interest Paid
15 1.30 14 3.22 9.55 5.44 31 8.16 16 12

Annual Balance Sheets for Alnylam Pharmaceuticals

This table presents Alnylam Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Total Assets
1,387 1,263 1,995 1,575 2,395 3,407 3,643 3,546 3,830 4,240
Total Current Assets
1,105 672 1,765 1,201 1,716 2,615 2,809 2,692 2,983 3,295
Cash & Equivalents
181 194 645 420 547 497 820 866 813 966
Short-Term Investments
900 433 1,045 664 989 1,378 1,616 1,326 1,627 1,728
Accounts Receivable
8.30 23 34 19 43 102 199 238 328 405
Inventories, net
- - - 24 56 75 86 129 89 79
Prepaid Expenses
17 22 40 74 80 63 88 133 126 117
Plant, Property, & Equipment, net
28 115 182 321 425 465 502 523 526 503
Total Noncurrent Assets
253 476 48 53 254 327 333 331 321 442
Long-Term Investments
252 475 44 45 15 41 41 49 49 69
Noncurrent Deferred & Refundable Income Taxes
- - - - - - - - 10 117
Other Noncurrent Operating Assets
1.47 1.56 4.17 8.62 239 287 292 281 262 256
Total Liabilities & Shareholders' Equity
1,387 1,263 1,995 1,575 2,395 3,407 3,643 3,546 3,830 4,240
Total Liabilities
122 343 228 273 956 2,391 3,055 3,705 4,051 4,173
Total Current Liabilities
62 132 144 179 353 585 696 768 968 1,186
Accounts Payable
17 54 28 60 50 52 73 98 56 88
Accrued Expenses
29 42 72 113 197 356 395 545 713 887
Current Deferred Revenue
17 35 44 7.07 78 127 149 42 103 55
Other Current Liabilities
- - - 0.00 28 50 78 82 97 155
Total Noncurrent Liabilities
60 211 84 93 604 1,614 2,359 2,937 3,083 2,987
Long-Term Debt
- 150 30 30 0.00 - 676 1,017 1,021 1,025
Noncurrent Deferred Revenue
58 58 50 58 318 225 152 194 188 0.00
Other Noncurrent Operating Liabilities
1.30 3.07 4.35 4.97 285 1,389 1,531 1,726 1,874 1,962
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
1,265 920 1,766 1,302 1,439 1,016 588 -158 -221 67
Total Preferred & Common Equity
1,265 920 1,766 1,302 1,439 1,016 588 -158 -221 67
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
1,265 920 1,766 1,302 1,439 1,016 588 -158 -221 67
Common Stock
2,507 2,610 3,949 4,176 5,202 5,645 6,060 6,456 6,812 7,389
Retained Earnings
-1,247 -1,657 -2,148 -2,841 -3,727 -4,585 -5,438 -6,569 -7,010 -7,288
Accumulated Other Comprehensive Income / (Loss)
4.37 -33 -34 -33 -37 -44 -33 -45 -23 -35

Quarterly Balance Sheets for Alnylam Pharmaceuticals

This table presents Alnylam Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets
3,535 3,392 3,402 3,839 3,824 4,010 4,205
Total Current Assets
2,691 2,541 2,524 2,985 2,989 3,173 3,355
Cash & Equivalents
1,073 672 658 1,033 682 968 1,100
Short-Term Investments
1,192 1,398 1,400 1,373 1,689 1,656 1,680
Accounts Receivable
185 219 221 325 321 309 354
Inventories, net
115 132 100 96 94 84 76
Prepaid Expenses
126 119 145 158 202 155 145
Plant, Property, & Equipment, net
515 523 527 526 523 517 507
Total Noncurrent Assets
330 328 351 328 312 320 343
Long-Term Investments
49 49 49 49 49 49 69
Other Noncurrent Operating Assets
280 279 301 279 263 270 274
Total Liabilities & Shareholders' Equity
3,535 3,392 3,402 3,839 3,824 4,010 4,205
Total Liabilities
3,603 3,651 3,811 4,005 4,044 4,013 4,173
Total Current Liabilities
773 673 789 950 942 1,055 1,221
Accounts Payable
41 62 60 74 78 74 71
Accrued Expenses
511 509 599 713 699 809 946
Current Deferred Revenue
144 36 55 77 77 69 71
Other Current Liabilities
77 67 76 86 88 104 133
Total Noncurrent Liabilities
2,830 2,978 3,022 3,055 3,102 2,957 2,952
Long-Term Debt
1,016 1,018 1,019 1,020 1,022 1,023 1,024
Noncurrent Deferred Revenue
133 191 194 196 186 2.40 1.01
Other Noncurrent Operating Liabilities
1,681 1,769 1,809 1,839 1,895 1,932 1,927
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
-68 -259 -408 -166 -219 -3.07 32
Total Preferred & Common Equity
-68 -259 -408 -166 -219 -3.07 32
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
-68 -259 -408 -166 -219 -3.07 32
Common Stock
6,338 6,523 6,648 6,738 6,883 7,124 7,261
Retained Earnings
-6,362 -6,743 -7,019 -6,872 -7,076 -7,092 -7,204
Accumulated Other Comprehensive Income / (Loss)
-44 -39 -37 -32 -27 -35 -25

Annual Metrics and Ratios for Alnylam Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Alnylam Pharmaceuticals' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Growth Metrics
- - - - - - - - - -
Revenue Growth
-18.72% 14.75% 90.66% -16.69% 193.36% 124.28% 71.31% 22.88% 76.23% 22.97%
EBITDA Growth
29.23% -45.65% -21.80% -57.71% -11.57% 19.40% 10.86% -40.86% 59.56% 14.97%
EBIT Growth
26.60% -41.39% -20.24% -57.01% -16.30% 16.07% 7.83% -29.34% 55.63% 12.34%
NOPAT Growth
26.91% -43.44% -17.78% -62.91% -15.31% 11.81% 14.46% -10.78% 64.06% 37.31%
Net Income Growth
19.51% -41.38% -19.69% -55.13% -16.37% 3.14% 0.64% -32.64% 61.08% 36.82%
EPS Growth
28.87% -38.84% -13.15% -39.67% -7.13% 8.01% 3.49% -29.17% 62.15% 38.07%
Operating Cash Flow Growth
-14.19% -62.68% -24.40% -46.98% 50.51% -120.87% -4.35% 15.65% 119.24% -107.98%
Free Cash Flow Firm Growth
51.25% -85.48% -32.94% -60.46% 51.88% 104.50% -42.16% -4,357.02% 128.50% -230.57%
Invested Capital Growth
-68.11% 53.62% 297.26% 227.96% -155.32% -530.12% -71.36% -14.06% -22.09% 1.02%
Revenue Q/Q Growth
-28.61% 26.58% 29.48% -18.40% 29.95% 22.91% 12.67% 7.96% 6.07% 7.33%
EBITDA Q/Q Growth
-19.40% -4.89% -6.99% -9.62% -7.04% 10.94% -3.27% -0.48% 2.89% -45.28%
EBIT Q/Q Growth
-18.75% -4.17% -6.64% -10.52% -7.26% 9.34% -2.93% 3.51% 11.77% -15.98%
NOPAT Q/Q Growth
-18.78% -5.71% -6.81% -9.85% -9.02% 11.14% -0.05% 0.75% 20.38% 5.98%
Net Income Q/Q Growth
-31.41% -5.73% -6.35% -10.00% -7.88% 3.66% -1.78% 4.31% 13.66% 16.28%
EPS Q/Q Growth
-45.57% -5.51% -3.24% -8.76% -4.38% 4.36% -0.84% 4.81% 15.18% 15.50%
Operating Cash Flow Q/Q Growth
-9.51% -8.95% -6.90% -9.20% -19.55% 10.59% -4.39% 3.25% 5,179.07% -114.70%
Free Cash Flow Firm Q/Q Growth
-3.81% -12.41% -4.44% -3.61% -38.06% 111.17% -77.55% -3.45% 949.02% -337.48%
Invested Capital Q/Q Growth
-27.09% 16.85% 4.91% -10.37% 12.81% -9.95% -2.84% -1.22% -5.43% 6.77%
Profitability Metrics
- - - - - - - - - -
Gross Margin
100.00% 100.00% 100.00% 97.59% 88.60% 84.16% 83.40% 83.73% 83.02% 85.62%
EBITDA Margin
-673.73% -855.16% -546.33% -1,034.19% -393.33% -141.35% -73.55% -84.32% -19.35% -13.38%
Operating Margin
-720.27% -900.33% -556.20% -1,087.56% -427.50% -168.09% -83.94% -75.68% -15.43% -7.87%
EBIT Margin
-720.08% -887.25% -559.56% -1,054.54% -418.07% -156.46% -84.18% -88.61% -22.31% -15.90%
Profit (Net Income) Margin
-705.83% -869.63% -545.95% -1,016.58% -403.24% -174.15% -101.01% -109.04% -24.08% -12.37%
Tax Burden Percent
100.00% 100.00% 100.00% 100.11% 100.10% 100.31% 100.08% 100.37% 101.55% 73.71%
Interest Burden Percent
98.02% 98.01% 97.57% 96.30% 96.36% 110.96% 119.90% 122.60% 106.29% 105.56%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% -2,294.21% -430.59% -1,450.22% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% -2,283.60% -416.95% -1,432.97% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 2,257.67% 380.96% 1,385.55% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-26.36% -37.54% -36.54% -49.63% -64.66% -69.92% -106.31% -526.14% 232.40% 362.29%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% -716.28% -537.12% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
-24.00% -31.59% -30.89% -44.26% -46.28% -26.58% -20.16% -25.57% -11.06% -8.86%
Return on Assets (ROA)
-23.52% -30.96% -30.14% -42.67% -44.64% -29.58% -24.19% -31.47% -11.94% -6.89%
Return on Common Equity (ROCE)
-26.36% -37.54% -36.54% -49.63% -64.66% -69.92% -106.31% -526.14% 232.40% 362.29%
Return on Equity Simple (ROE_SIMPLE)
-22.94% -44.57% -27.79% -58.49% -61.59% -84.46% -144.99% 714.91% 199.53% -414.62%
Net Operating Profit after Tax (NOPAT)
-207 -297 -350 -570 -658 -580 -496 -550 -198 -124
NOPAT Margin
-504.19% -630.23% -389.34% -761.30% -299.25% -117.66% -58.75% -52.97% -10.80% -5.51%
Net Nonoperating Expense Percent (NNEP)
-7.18% -9.89% -10.60% -13.64% -17.25% -17.00% -20.24% -38.45% -18.03% -9.63%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - -64.00% -24.69% -11.34%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 2.41% 11.40% 15.84% 16.60% 16.27% 16.98% 14.38%
SG&A Expenses to Revenue
147.48% 189.47% 221.73% 510.44% 217.98% 119.39% 73.51% 74.29% 43.52% 43.39%
R&D to Revenue
672.79% 810.86% 434.46% 674.72% 298.12% 132.86% 93.83% 85.12% 54.94% 50.09%
Operating Expenses to Revenue
820.27% 1,000.33% 656.20% 1,185.16% 516.10% 252.25% 167.34% 159.40% 98.46% 93.48%
Earnings before Interest and Taxes (EBIT)
-296 -418 -503 -790 -919 -771 -711 -919 -408 -358
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-277 -403 -491 -775 -864 -697 -621 -875 -354 -301
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
6.31 3.49 6.67 5.66 8.93 14.86 34.48 0.00 0.00 452.40
Price to Tangible Book Value (P/TBV)
6.31 3.49 6.67 5.66 8.93 14.86 34.48 0.00 0.00 452.40
Price to Revenue (P/Rev)
194.10 68.13 131.03 98.34 58.43 30.64 24.02 28.18 13.14 13.50
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 162.81 30.87 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
161.68 47.95 112.08 83.66 51.37 26.75 21.89 27.00 12.34 12.73
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 216.53 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 856.53 2,075.70 0.00 208.74 0.00
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
0.00 0.16 0.02 0.02 0.00 0.00 1.15 -6.43 -4.63 15.27
Long-Term Debt to Equity
0.00 0.16 0.02 0.02 0.00 0.00 1.15 -6.43 -4.63 15.27
Financial Leverage
-1.05 -1.05 -0.99 -0.91 -0.97 -1.33 -2.20 -7.04 7.11 20.88
Leverage Ratio
1.12 1.21 1.21 1.16 1.45 2.36 4.39 16.72 -19.47 -52.55
Compound Leverage Factor
1.10 1.19 1.18 1.12 1.40 2.62 5.27 20.50 -20.69 -55.47
Debt to Total Capital
0.00% 14.02% 1.67% 2.25% 0.00% 0.00% 53.46% 118.43% 127.58% 93.85%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 14.02% 1.67% 2.25% 0.00% 0.00% 53.46% 118.43% 127.58% 93.85%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 85.98% 98.33% 97.75% 100.00% 100.00% 46.54% -18.43% -27.58% 6.15%
Debt to EBITDA
0.00 -0.37 -0.06 -0.04 0.00 0.00 -1.09 -1.16 -2.89 -3.41
Net Debt to EBITDA
0.00 2.36 3.47 1.42 0.00 0.00 2.90 1.40 4.15 5.78
Long-Term Debt to EBITDA
0.00 -0.37 -0.06 -0.04 0.00 0.00 -1.09 -1.16 -2.89 -3.41
Debt to NOPAT
0.00 -0.50 -0.09 -0.05 0.00 0.00 -1.36 -1.85 -5.17 -8.28
Net Debt to NOPAT
0.00 3.20 4.87 1.93 0.00 0.00 3.63 2.23 7.43 14.04
Long-Term Debt to NOPAT
0.00 -0.50 -0.09 -0.05 0.00 0.00 -1.36 -1.85 -5.17 -8.28
Altman Z-Score
38.27 3.25 29.64 12.84 5.39 2.02 2.18 2.23 1.75 2.81
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
17.80 5.10 12.23 6.69 4.87 4.47 4.04 3.51 3.08 2.78
Quick Ratio
17.53 4.94 11.96 6.14 4.48 3.38 3.79 3.16 2.86 2.61
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-180 -333 -443 -711 -342 15 8.90 -379 108 -141
Operating Cash Flow to CapEx
-1,460.54% -476.63% -367.33% -443.40% -198.66% -874.01% -840.22% -751.15% 167.42% -24.25%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.18 0.06 -1.63 0.89 -0.99
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 -7.28 -4.49 -2.33 0.86 -0.06
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 -8.11 -5.02 -2.64 0.35 -0.30
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.03 0.04 0.06 0.04 0.11 0.17 0.24 0.29 0.50 0.56
Accounts Receivable Turnover
1.70 2.98 3.14 2.84 7.12 6.78 5.61 4.75 6.46 6.13
Inventory Turnover
0.00 0.00 0.00 0.00 0.62 1.19 1.73 1.57 2.85 3.86
Fixed Asset Turnover
1.66 0.66 0.61 0.30 0.59 1.11 1.75 2.02 3.48 4.37
Accounts Payable Turnover
0.00 0.00 0.00 0.04 0.46 1.53 2.24 1.97 4.04 4.49
Days Sales Outstanding (DSO)
214.20 122.41 116.38 128.55 51.30 53.85 65.06 76.79 56.47 59.51
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 585.58 307.59 210.40 232.78 128.23 94.62
Days Payable Outstanding (DPO)
0.00 0.00 0.00 8,918.70 798.04 238.14 163.29 185.42 90.32 81.23
Cash Conversion Cycle (CCC)
214.20 122.41 116.38 -8,790.15 -161.16 123.29 112.17 124.15 94.39 72.90
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
-68 -31 62 203 -112 -708 -1,213 -1,383 -1,689 -1,671
Invested Capital Turnover
-0.76 -0.95 5.89 0.57 4.85 -1.20 -0.88 -0.80 -1.19 -1.34
Increase / (Decrease) in Invested Capital
-27 36 93 141 -315 -595 -505 -171 -306 17
Enterprise Value (EV)
6,645 2,261 10,077 6,267 11,289 13,185 18,481 28,013 22,553 28,612
Market Capitalization
7,977 3,213 11,781 7,366 12,840 15,100 20,282 29,238 24,021 30,350
Book Value per Share
$14.93 $10.72 $19.05 $12.89 $12.90 $8.75 $4.92 ($1.29) ($1.76) $0.52
Tangible Book Value per Share
$14.93 $10.72 $19.05 $12.89 $12.90 $8.75 $4.92 ($1.29) ($1.76) $0.52
Total Capital
1,265 1,070 1,796 1,332 1,439 1,016 1,264 859 800 1,092
Total Debt
0.00 150 30 30 0.00 0.00 676 1,017 1,021 1,025
Total Long-Term Debt
0.00 150 30 30 0.00 0.00 676 1,017 1,021 1,025
Net Debt
-1,332 -952 -1,705 -1,099 -1,551 -1,915 -1,801 -1,225 -1,468 -1,738
Capital Expenditures (CapEx)
13 65 104 127 140 70 76 72 62 34
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-37 -87 -70 -63 -173 155 -323 -268 -424 -585
Debt-free Net Working Capital (DFNWC)
1,043 540 1,620 1,021 1,363 2,030 2,113 1,924 2,015 2,109
Net Working Capital (NWC)
1,043 540 1,620 1,021 1,363 2,030 2,113 1,924 2,015 2,109
Net Nonoperating Expense (NNE)
83 113 141 191 229 278 357 582 243 154
Net Nonoperating Obligations (NNO)
-1,332 -952 -1,705 -1,099 -1,551 -1,724 -1,801 -1,225 -1,468 -1,738
Total Depreciation and Amortization (D&A)
19 15 12 15 54 74 90 44 54 57
Debt-free, Cash-free Net Working Capital to Revenue
-90.62% -183.68% -78.00% -84.04% -78.68% 31.47% -38.22% -25.84% -23.22% -26.04%
Debt-free Net Working Capital to Revenue
2,538.60% 1,145.44% 1,802.31% 1,363.28% 620.37% 411.79% 250.25% 185.49% 110.21% 93.81%
Net Working Capital to Revenue
2,538.60% 1,145.44% 1,802.31% 1,363.28% 620.37% 411.79% 250.25% 185.49% 110.21% 93.81%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
($3.45) ($4.79) ($5.42) ($7.57) ($8.11) ($7.46) ($7.20) ($9.30) ($3.52) ($2.18)
Adjusted Weighted Average Basic Shares Outstanding
85.14M 86.01M 99.87M 106.26M 112.58M 117.00M 118.45M 121.69M 124.91M 127.65M
Adjusted Diluted Earnings per Share
($3.45) ($4.79) ($5.42) ($7.57) ($8.11) ($7.46) ($7.20) ($9.30) ($3.52) ($2.18)
Adjusted Weighted Average Diluted Shares Outstanding
85.14M 86.01M 99.87M 106.26M 112.58M 117.00M 118.45M 121.69M 124.91M 127.65M
Adjusted Basic & Diluted Earnings per Share
($3.45) ($4.79) ($5.42) ($7.57) ($8.11) ($7.46) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
83.99M 85.60M 90.55M 100.59M 109.26M 114.99M 120.21M 124.13M 125.95M 129.46M
Normalized Net Operating Profit after Tax (NOPAT)
-207 -297 -350 -570 -658 -580 -496 -550 -198 -124
Normalized NOPAT Margin
-504.19% -630.23% -389.34% -761.30% -299.25% -117.66% -58.75% -52.97% -10.80% -5.51%
Pre Tax Income Margin
-705.83% -869.63% -545.95% -1,015.48% -402.85% -173.60% -100.93% -108.63% -23.71% -16.79%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 -9.13 -4.97 -3.95 -3.36 -2.52
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 -6.86 -3.47 -2.36 -1.63 -0.87
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 -9.96 -5.50 -4.26 -3.88 -2.76
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 -7.70 -4.00 -2.67 -2.14 -1.11
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for Alnylam Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Alnylam Pharmaceuticals' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics
- - - - - - - - - -
Revenue Growth
40.86% 29.59% 49.72% 41.78% 183.96% 31.25% 54.82% 107.00% -33.26% 34.90%
EBITDA Growth
-95.71% 12.94% 23.70% -13.14% 165.26% 30.30% 76.11% 107.28% -144.17% -39.40%
EBIT Growth
-80.59% 14.88% 18.15% -13.37% 152.76% 28.47% 64.22% 97.33% -168.14% -36.01%
NOPAT Growth
-42.03% 3.06% -2.10% -19.90% 216.05% 38.28% 71.01% 121.15% -125.68% 9.66%
Net Income Growth
-98.48% 19.72% 27.56% 0.50% 136.40% 33.55% 62.13% 93.88% -175.51% 39.24%
EPS Growth
-93.02% 21.76% 30.00% 3.49% 134.64% 37.28% 62.86% 94.12% -175.65% 37.74%
Operating Cash Flow Growth
13.99% 12.10% 2.76% 51.97% 411.76% 77.42% 51.03% 310.49% -87.84% -217.71%
Free Cash Flow Firm Growth
-98.36% -89.56% -88.45% -94.39% 6,551.30% 482.15% 319.44% 561.59% -69.15% -140.55%
Invested Capital Growth
-15.89% -14.06% -13.21% -14.54% -17.22% -22.09% -18.86% -10.58% -11.93% 1.02%
Revenue Q/Q Growth
17.56% 26.76% -4.70% -0.17% 135.46% -41.41% 12.42% 33.48% -24.08% 18.42%
EBITDA Q/Q Growth
-28.88% 35.79% 18.23% -77.82% 174.33% -168.58% 71.19% 154.17% -551.08% -116.43%
EBIT Q/Q Growth
-26.56% 35.43% 15.23% -63.67% 158.89% -187.55% 57.60% 87.77% -1,400.96% -74.76%
NOPAT Q/Q Growth
-34.62% 26.91% 20.57% -53.42% 230.30% -138.87% 62.69% 211.92% -258.20% -36.74%
Net Income Q/Q Growth
-46.33% 48.88% 16.09% -58.54% 153.53% -193.31% 52.18% 74.39% -560.61% 24.92%
EPS Q/Q Growth
-44.98% 49.10% 17.16% -57.86% 152.04% -192.17% 50.94% 75.00% -569.23% 24.14%
Operating Cash Flow Q/Q Growth
6.14% -14.48% -26.14% 64.57% 709.32% -108.29% -173.59% 252.31% -64.80% -316.58%
Free Cash Flow Firm Q/Q Growth
-98.71% 475.37% 40.22% -46.16% 1,431.15% -49.64% 1.03% -15.07% -28.61% -166.20%
Invested Capital Q/Q Growth
-4.60% -1.22% 1.57% -9.90% -7.05% -5.43% 4.17% -2.24% -8.37% 6.77%
Profitability Metrics
- - - - - - - - - -
Gross Margin
84.44% 84.70% 82.82% 73.22% 88.77% 80.47% 86.65% 89.59% 82.85% 82.67%
EBITDA Margin
-104.21% -52.79% -42.59% -75.86% 23.95% -28.03% -6.57% 2.67% -15.85% -28.97%
Operating Margin
-97.63% -56.30% -46.92% -72.10% 28.50% -26.47% -8.79% 7.37% -15.35% -17.73%
EBIT Margin
-112.03% -57.06% -50.76% -83.21% 20.81% -31.10% -11.73% -1.07% -21.25% -31.36%
Profit (Net Income) Margin
-153.58% -61.93% -54.53% -86.59% 19.69% -31.35% -13.34% -2.56% -22.27% -14.12%
Tax Burden Percent
99.99% 100.23% 101.01% 100.66% 98.02% 100.13% 103.69% 151.24% 102.68% 43.19%
Interest Burden Percent
137.10% 108.28% 106.36% 103.38% 96.50% 100.68% 109.67% 157.48% 102.10% 104.28%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 1.98% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-343.51% -526.14% -1,500.66% 916.48% 436.71% 232.40% 138.80% 35.48% 497.73% 362.29%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
-30.72% -16.47% -17.01% -30.59% 9.73% -15.42% -6.51% -0.68% -11.07% -17.47%
Return on Assets (ROA)
-42.12% -17.87% -18.27% -31.83% 9.20% -15.54% -7.41% -1.62% -11.60% -7.87%
Return on Common Equity (ROCE)
-343.51% -526.14% -1,500.66% 916.48% 436.71% 232.40% 138.80% 35.48% 497.73% 362.29%
Return on Equity Simple (ROE_SIMPLE)
1,747.72% 0.00% 410.78% 260.59% 307.40% 0.00% 151.44% 2,378.25% -1,026.96% 0.00%
Net Operating Profit after Tax (NOPAT)
-181 -132 -105 -161 210 -81 -30 34 -54 -74
NOPAT Margin
-68.34% -39.41% -32.84% -50.47% 27.93% -18.53% -6.15% 5.16% -10.75% -12.41%
Net Nonoperating Expense Percent (NNEP)
-13.93% -4.99% -5.12% -8.96% -4.53% -4.19% -2.84% -3.72% -3.54% -0.63%
Return On Investment Capital (ROIC_SIMPLE)
- -15.38% - - - -10.18% - - - -6.74%
Cost of Revenue to Revenue
15.56% 15.30% 17.18% 26.78% 11.23% 19.53% 13.35% 10.41% 17.15% 17.33%
SG&A Expenses to Revenue
89.24% 62.78% 57.52% 67.35% 26.54% 45.06% 42.64% 37.65% 44.12% 49.79%
R&D to Revenue
92.84% 78.21% 72.21% 77.97% 33.73% 61.89% 52.80% 44.58% 54.09% 50.60%
Operating Expenses to Revenue
182.07% 141.00% 129.73% 145.32% 60.27% 106.95% 95.44% 82.22% 98.20% 100.39%
Earnings before Interest and Taxes (EBIT)
-296 -191 -162 -265 156 -137 -58 -7.09 -106 -186
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-275 -177 -136 -242 180 -123 -32 18 -79 -172
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1,091.32 452.40
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1,091.32 452.40
Price to Revenue (P/Rev)
25.00 28.18 21.75 19.11 12.84 13.14 9.36 13.11 16.86 13.50
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
23.65 27.00 20.78 18.24 12.01 12.34 8.66 12.41 15.98 12.73
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 558.63 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 404.82 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 10,492.53 216.53 91.77 78.13 592.05 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 208.74 129.78 126.41 563.66 0.00
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
-15.02 -6.43 -3.93 -2.50 -6.15 -4.63 -4.66 -333.45 31.64 15.27
Long-Term Debt to Equity
-15.02 -6.43 -3.93 -2.50 -6.15 -4.63 -4.66 -333.45 31.64 15.27
Financial Leverage
-4.70 -7.04 -19.07 11.07 11.71 7.11 5.23 6.66 24.43 20.88
Leverage Ratio
10.18 16.72 48.09 -29.01 -31.58 -19.47 -15.08 -18.03 -60.25 -52.55
Compound Leverage Factor
13.96 18.11 51.15 -29.99 -30.48 -19.60 -16.54 -28.39 -61.51 -54.80
Debt to Total Capital
107.13% 118.43% 134.17% 166.83% 119.42% 127.58% 127.33% 100.30% 96.94% 93.85%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
107.13% 118.43% 134.17% 166.83% 119.42% 127.58% 127.33% 100.30% 96.94% 93.85%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
-7.13% -18.43% -34.17% -66.83% -19.42% -27.58% -27.33% -0.30% 3.06% 6.15%
Debt to EBITDA
-1.17 -1.16 -1.29 -1.24 -2.80 -2.89 -4.93 19.64 -4.94 -3.41
Net Debt to EBITDA
1.49 1.40 1.39 1.33 3.94 4.15 6.75 -31.72 8.81 5.78
Long-Term Debt to EBITDA
-1.17 -1.16 -1.29 -1.24 -2.80 -2.89 -4.93 19.64 -4.94 -3.41
Debt to NOPAT
-1.83 -1.85 -1.85 -1.76 -4.11 -5.17 -8.30 14.23 -7.77 -8.28
Net Debt to NOPAT
2.35 2.23 2.00 1.88 5.79 7.43 11.37 -22.98 13.86 14.04
Long-Term Debt to NOPAT
-1.83 -1.85 -1.85 -1.76 -4.11 -5.17 -8.30 14.23 -7.77 -8.28
Altman Z-Score
2.13 2.91 2.14 1.55 2.03 1.99 1.31 3.33 3.70 2.94
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
3.48 3.51 3.77 3.20 3.14 3.08 3.17 3.01 2.75 2.78
Quick Ratio
3.17 3.16 3.40 2.89 2.88 2.86 2.86 2.78 2.57 2.61
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
6.69 38 54 29 445 224 226 192 137 -91
Operating Cash Flow to CapEx
-698.27% -610.02% -1,198.44% -370.54% 2,102.81% -194.62% -628.34% 1,548.49% 1,042.63% -1,040.93%
Free Cash Flow to Firm to Interest Expense
0.06 1.29 1.86 0.97 14.40 7.15 6.42 5.78 3.99 -2.33
Operating Cash Flow to Interest Expense
-0.98 -4.41 -5.75 -1.96 11.63 -0.95 -2.31 3.73 1.27 -2.43
Operating Cash Flow Less CapEx to Interest Expense
-1.12 -5.14 -6.23 -2.49 11.08 -1.44 -2.68 3.49 1.15 -2.66
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.27 0.29 0.34 0.37 0.47 0.50 0.56 0.63 0.52 0.56
Accounts Receivable Turnover
5.90 4.75 6.08 6.82 6.76 6.46 7.41 8.84 6.17 6.13
Inventory Turnover
1.45 1.57 1.79 2.46 2.61 2.85 2.85 3.31 3.57 3.86
Fixed Asset Turnover
1.92 2.02 2.23 2.39 3.31 3.48 3.83 4.49 4.06 4.37
Accounts Payable Turnover
3.85 1.97 3.21 4.15 4.82 4.04 4.58 4.56 4.24 4.49
Days Sales Outstanding (DSO)
61.83 76.79 60.01 53.52 54.00 56.47 49.27 41.27 59.18 59.51
Days Inventory Outstanding (DIO)
250.90 232.78 204.18 148.61 139.79 128.23 128.21 110.43 102.30 94.62
Days Payable Outstanding (DPO)
94.79 185.42 113.69 88.00 75.70 90.32 79.69 80.06 86.15 81.23
Cash Conversion Cycle (CCC)
217.94 124.15 150.49 114.14 118.08 94.39 97.79 71.63 75.33 72.90
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
-1,366 -1,383 -1,361 -1,496 -1,602 -1,689 -1,618 -1,654 -1,793 -1,671
Invested Capital Turnover
-0.76 -0.80 -0.89 -0.88 -1.16 -1.19 -1.34 -1.49 -1.23 -1.34
Increase / (Decrease) in Invested Capital
-187 -171 -159 -190 -235 -306 -257 -158 -191 17
Enterprise Value (EV)
22,726 28,013 23,764 22,564 20,702 22,553 17,356 29,086 33,483 28,612
Market Capitalization
24,025 29,238 24,866 23,652 22,138 24,021 18,755 30,738 35,308 30,350
Book Value per Share
($0.56) ($1.29) ($2.09) ($3.28) ($1.33) ($1.76) ($1.74) ($0.02) $0.25 $0.52
Tangible Book Value per Share
($0.56) ($1.29) ($2.09) ($3.28) ($1.33) ($1.76) ($1.74) ($0.02) $0.25 $0.52
Total Capital
948 859 759 611 854 800 802 1,020 1,056 1,092
Total Debt
1,016 1,017 1,018 1,019 1,020 1,021 1,022 1,023 1,024 1,025
Total Long-Term Debt
1,016 1,017 1,018 1,019 1,020 1,021 1,022 1,023 1,024 1,025
Net Debt
-1,299 -1,225 -1,102 -1,088 -1,436 -1,468 -1,399 -1,651 -1,825 -1,738
Capital Expenditures (CapEx)
17 22 14 16 17 15 13 8.02 4.19 9.09
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-347 -268 -203 -322 -371 -424 -324 -507 -645 -585
Debt-free Net Working Capital (DFNWC)
1,918 1,924 1,868 1,735 2,036 2,015 2,047 2,118 2,135 2,109
Net Working Capital (NWC)
1,918 1,924 1,868 1,735 2,036 2,015 2,047 2,118 2,135 2,109
Net Nonoperating Expense (NNE)
225 75 69 115 62 56 36 51 58 10
Net Nonoperating Obligations (NNO)
-1,299 -1,225 -1,102 -1,088 -1,436 -1,468 -1,399 -1,651 -1,825 -1,738
Total Depreciation and Amortization (D&A)
21 14 26 23 24 13 25 25 27 14
Debt-free, Cash-free Net Working Capital to Revenue
-36.14% -25.84% -17.76% -26.03% -21.50% -23.22% -16.19% -21.63% -30.81% -26.04%
Debt-free Net Working Capital to Revenue
199.61% 185.49% 163.33% 140.25% 118.10% 110.21% 102.17% 90.33% 101.91% 93.81%
Net Working Capital to Revenue
199.61% 185.49% 163.33% 140.25% 118.10% 110.21% 102.17% 90.33% 101.91% 93.81%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
($3.32) ($1.69) ($1.40) ($2.21) $1.18 ($1.09) ($0.52) ($0.13) ($0.87) ($0.66)
Adjusted Weighted Average Basic Shares Outstanding
122.17M 121.69M 124.11M 124.66M 125.22M 124.91M 126.14M 126.73M 128.59M 127.65M
Adjusted Diluted Earnings per Share
($3.32) ($1.69) ($1.40) ($2.21) $1.15 ($1.06) ($0.52) ($0.13) ($0.87) ($0.66)
Adjusted Weighted Average Diluted Shares Outstanding
122.17M 121.69M 124.11M 124.66M 131.34M 124.91M 126.14M 126.73M 128.59M 127.65M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
123.03M 124.13M 124.53M 125.00M 125.49M 125.95M 126.49M 128.38M 128.98M 129.46M
Normalized Net Operating Profit after Tax (NOPAT)
-181 -132 -105 -161 210 -81 -30 34 -54 -74
Normalized NOPAT Margin
-68.34% -39.41% -32.84% -50.47% 27.93% -18.53% -6.15% 5.16% -10.75% -12.41%
Pre Tax Income Margin
-153.59% -61.79% -53.98% -86.03% 20.08% -31.31% -12.86% -1.69% -21.69% -32.70%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
-2.52 -6.39 -5.60 -8.83 5.06 -4.36 -1.64 -0.21 -3.10 -4.77
NOPAT to Interest Expense
-1.54 -4.41 -3.62 -5.36 6.79 -2.60 -0.86 1.02 -1.57 -1.89
EBIT Less CapEx to Interest Expense
-2.66 -7.11 -6.08 -9.36 4.50 -4.85 -2.01 -0.45 -3.22 -5.01
NOPAT Less CapEx to Interest Expense
-1.68 -5.14 -4.10 -5.89 6.23 -3.09 -1.23 0.78 -1.69 -2.12
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Alnylam Pharmaceuticals' Financials

When does Alnylam Pharmaceuticals's fiscal year end?

According to the most recent income statement we have on file, Alnylam Pharmaceuticals' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Alnylam Pharmaceuticals' net income changed over the last 9 years?

Alnylam Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$278.16 million in 2024, falling from -$290.07 million in 2015. The previous period was -$440.24 million in 2023.

What is Alnylam Pharmaceuticals's operating income?
Alnylam Pharmaceuticals's total operating income in 2024 was -$176.89 million, based on the following breakdown:
  • Total Gross Profit: $1.92 billion
  • Total Operating Expenses: $2.10 billion
How has Alnylam Pharmaceuticals revenue changed over the last 9 years?

Over the last 9 years, Alnylam Pharmaceuticals' total revenue changed from $41.10 million in 2015 to $2.25 billion in 2024, a change of 5,370.6%.

How much debt does Alnylam Pharmaceuticals have?

Alnylam Pharmaceuticals' total liabilities were at $4.17 billion at the end of 2024, a 3.0% increase from 2023, and a 3,326.1% increase since 2015.

How much cash does Alnylam Pharmaceuticals have?

In the past 9 years, Alnylam Pharmaceuticals' cash and equivalents has ranged from $180.90 million in 2015 to $966.43 million in 2024, and is currently $966.43 million as of their latest financial filing in 2024.

How has Alnylam Pharmaceuticals' book value per share changed over the last 9 years?

Over the last 9 years, Alnylam Pharmaceuticals' book value per share changed from 14.93 in 2015 to 0.52 in 2024, a change of -96.5%.

Remove Ads


This page (NASDAQ:ALNY) was last updated on 4/15/2025 by MarketBeat.com Staff
From Our Partners